Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial

To explore the efficacy and safety of cryoablation combined with hepatic arterial infusion of iparomlimab and tuvonralimab, intravenous dacarbazine, and oral lenvatinib in patients with liver metastases from malignant melanoma.

Trial Details

NCT ID
NCT07847359
Phase
PHASE2
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Cryoablation
  • Iparomlimab and Tuvonralimab
  • Dacarbazine
  • Lenvatinib
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Age 18-70 years;
  • Patients with pathologically confirmed metastatic malignant melanoma after failure of standard treatment;
  • Presence of liver metastases, with at least one lesion assessed as suitable for cryoablation;
  • The largest diameter of each intrahepatic metastatic lesion \< 5 cm;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →